logo

For the Inventor, By the Inventor

Shanghai, China

Shuhui Wang

This inventor holds 5 USPTO granted patents and 2 EPO patents. Top assignees: Shanghai Allist Pharmaceuticals Co., Ltd., Shanghai Allist Pharmaceuticals, Inc., Shanghai Biomabs Pharmaceuticals Co., Ltd.. Active years: 2014-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Shuhui Wang. Retrieved from https://idiyas.com/inventor/shuhui-wang-dd27ab9z

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 5

% Patents Active = 100.0

 

Average Co-Inventor Count = 4.4

ph-index = 2

Forward Citations = 6(Granted Patents)


Company Filing History:

goldMedal2 out of 2 
 
Shanghai Allist Pharmaceuticals Co., Ltd.
 patents
silverMedal1 out of 12 
 
Shanghai Allist Pharmaceuticals, Inc.
 patents
bronzeMedal1 out of 5 
 
Shanghai Biomabs Pharmaceuticals Co., Ltd.
 patents
4. 1 out of 248 
 
Tongji University
 patents
5. 1 out of 6,038 
 
Zte Corporation
 patents
where one patent can have more than one assignee

Years Active: 2014-2024

Loading Chart...
Loading Chart...
5 patents (USPTO):Explore Patents
1. RE49851 - Pyridinylaminopyrimidine derivatives, preparation process and use thereof (2024-02-27),
2. RE48687 - Pyridinylaminopyrimidine derivatives, preparation process and use thereof (2021-08-16),
3. 10820016 - Encoding and decoding method and device for data compression (2020-10-27),
4. 10072002 - Pyridinylaminopyrimidine derivatives, preparation process and use thereof (2018-09-11),
5. 8664368 - Fully human monoclonal antibody to VEGF, preparation method and use thereof (2014-03-04),

Title: Shuhui Wang: Innovator in Pharmaceutical Chemistry

Introduction

Shuhui Wang is a prominent inventor based in Shanghai, China. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of innovative compounds for cancer treatment. With a total of 5 patents, his work has garnered attention for its potential therapeutic applications.

Latest Patents

One of Wang's latest patents is focused on pyridinylaminopyrimidine derivatives. This invention relates to compounds that can selectively inhibit the activity of mutant-type epidermal growth factor receptor (EGFR). These derivatives have shown promising results in inhibiting cancer cell proliferation, making them potential therapeutic agents for treating tumors and related diseases.

Career Highlights

Wang has worked with notable organizations such as Shanghai Allist Pharmaceuticals Co., Ltd. and Tongji University. His experience in these institutions has allowed him to advance his research and contribute to the development of effective pharmaceutical solutions.

Collaborations

Wang has collaborated with esteemed colleagues, including Huibing Luo and Huayong Zhou. These partnerships have facilitated the exchange of ideas and expertise, further enhancing the impact of his work in the field.

Conclusion

Shuhui Wang's innovative contributions to pharmaceutical chemistry highlight his dedication to advancing cancer treatment. His patents and collaborations reflect a commitment to improving therapeutic options for patients.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…